Cited 0 times in 
Cited 0 times in 
An Open-Label, Multicentre, Phase 2 Study Of Trastuzumab Deruxtecan In Patients With HER2-Expressing Solid Tumours: DESTINY-PanTumor02 Part 2
https://orcid.org/0000-0001-7948-1350Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.